Twenty year Risk of Prostate Cancer Death by Midlife Prostate specific Antigen and a Panel of Four Kallikrein Markers in a Large Population based Cohort of Healthy Men

BACKGROUND: Prostate-specific antigen (PSA) screening reduces prostate cancer deaths but leads to harm from overdiagnosis and overtreatment. OBJECTIVE: To determine the long-term risk of prostate cancer mortality using kallikrein blood markers measured at baseline in a large population of healthy me...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Urol
Autors principals: Sjoberg, Daniel D., Vickers, Andrew J., Assel, Melissa, Dahlin, Anders, Poon, Bing Ying, Ulmert, David, Lilja, Hans Gösta
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5960423/
https://ncbi.nlm.nih.gov/pubmed/29519548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2018.02.016
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars